Pro Medicus Stock

Pro Medicus ROE

The Return on Equity (ROE) of Pro Medicus (PME.AX) as of Sep 12, 2026 is 44.84 %. In the previous year, Return on Equity (ROE) was 44.10 % — a change of 1.67% (higher).

ROE

44.84 %

YoY

1.67%

Last updated:

In 2026, Pro Medicus's return on equity (ROE) was 44.84 %, a 1.67% increase from the 44.10 % ROE in the previous year.

The Pro Medicus ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
28.42 AUD
Jan 1, 2019
38.80 AUD
Jan 1, 2020
38.34 AUD
Jan 1, 2021
37.77 AUD
Jan 1, 2022
43.69 AUD
Jan 1, 2023
43.70 AUD
Jan 1, 2024
44.10 AUD
Jan 1, 2025
44.84 AUD
The Pro Medicus ROE history
YEARROEYoY
44.84 %+1.67%
44.10 %+0.92%
43.70 %+0.04%
43.69 %+15.67%
37.77 %-1.50%
38.34 %-1.18%
38.80 %+36.55%
28.42 %+6.19%
26.76 %+15.07%
23.25 %+58.58%
14.66 %+101.12%
7.29 %—
Access this data via the Eulerpool API
Get Free API Key

Pro Medicus Stock analysis

What does Pro Medicus do? Pro Medicus Ltd. is an Australian company specializing in the development and distribution of medical imaging software solutions. The company was founded in 1983 and is headquartered in Melbourne. Pro Medicus is one of the most popular companies on Eulerpool.

ROE Details

Decoding Pro Medicus's Return on Equity (ROE)

Pro Medicus's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Pro Medicus's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Pro Medicus's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Pro Medicus’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Pro Medicus stock

Return on Equity (ROE) of Pro Medicus is 44.84 % in 2026.

Return on Equity (ROE) of Pro Medicus changed from 44.10 % to 44.84 %, representing a 1.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Pro Medicus since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Pro Medicus with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Pro Medicus

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Pro Medicus